Walmart’s latest brand and logo update has left some social media ... In a statement, William White, senior vice president and chief marketing officer, Walmart U.S, said, in part, “This ...

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Immunovant (IMVT – Research Report), retaining the price target of $50.00. Sam Slutsky’s rating is based on several positive ...

The Defense Intelligence Agency has paused activities and events related to Black History Month, Martin Luther King Jr. Day, Juneteenth and other "special observances" to comply with executive ...

In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other stocks. A lot is happening in the market, especially within the growth sectors.

We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other stocks. A lot is ...

Immunovant, Inc. (NASDAQ:IMVT) is a biotechnology company that ranks eighth on our list of stocks expected to double in 2025. IMVT has a focus on developing advanced treatments for patients with ...

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) reached a new 52-week low on Monday after an insider sold shares in the company. The company traded as low as $22.35 and last traded at $22.38 ...

Analyst Brian Cheng of J.P. Morgan maintained a Buy rating on Immunovant (IMVT – Research Report), with a price target of $46.00. Brian Cheng’s rating is based on the promising potential of ...

Immunovant, Inc. (NASDAQ:IMVT), a biopharmaceutical company specializing in biological products currently valued at $3.4 billion, has registered shares for resale by certain selling stockholders, ...